Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vertigo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: Vertigo. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-004025-27 Sponsor Protocol Number: Antivert1-B09_PE_V1.0 Start Date*: 2013-02-15
    Sponsor Name:HENNIG ARZNEIMITTEL GmbH & Co. KG
    Full Title: Efficacy and safety of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg vs betahistine dihydrochloride 16 mg in patients with vertigo of peripheral origin. A multi-centre, double-b...
    Medical condition: Vertigo of peripheral origin
    Disease: Version SOC Term Classification Code Term Level
    15.0 10013993 - Ear and labyrinth disorders 10031615 Other and unspecified peripheral vertigo LLT
    14.1 10013993 - Ear and labyrinth disorders 10058708 Rotatory vertigo LLT
    14.1 10013993 - Ear and labyrinth disorders 10047344 Vertigo labyrinthine PT
    14.1 10013993 - Ear and labyrinth disorders 10034641 Peripheral vertigo, unspecified LLT
    15.0 10013993 - Ear and labyrinth disorders 10032379 Other peripheral vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-003412-23 Sponsor Protocol Number: V00251IV2024A Start Date*: 2012-01-25
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.
    Medical condition: V0251 is a new antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000316-15 Sponsor Protocol Number: 523079.01.114 Start Date*: 2016-09-17
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Different Types of Vertigo and Effect Modification by Type of Vertigo, Chronicity and Concomitant Path...
    Medical condition: Different types of vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005122-33 Sponsor Protocol Number: NIMOBET-1 Start Date*: 2014-03-04
    Sponsor Name:MDM S.p.A.
    Full Title: A phase II, randomized, double-blind, parallel groups study to assess the efficacy and safety of Nimodipine 20 mg + Betahistine 16 mg versus Placebo + Betahistine 16 mg in the treatment of vertigo
    Medical condition: Vertigo
    Disease: Version SOC Term Classification Code Term Level
    16.1 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000303-28 Sponsor Protocol Number: MW029 Start Date*: 2014-09-29
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, prospective, controlled, randomized, single-blinded study to evaluate the efficacy of vibrotactile neuro-feedback additionally to intake of Ginkgo biloba special extract EGb 761® for ...
    Medical condition: Presby Vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005054-23 Sponsor Protocol Number: V00251 IV 201 Start Date*: 2007-12-07
    Sponsor Name:PIERRE FABRE MEDICAMENT - IRPF
    Full Title: A double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis.
    Medical condition: V0251 is a new investigational antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047340 Vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) DE (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004496-71 Sponsor Protocol Number: 104-201508 Start Date*: 2016-03-01
    Sponsor Name:Otonomy Inc.
    Full Title: A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere’...
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005913-37 Sponsor Protocol Number: no sponsor Start Date*: 2009-03-09
    Sponsor Name:UMC Utrecht
    Full Title: Intratympanic gentamicin therapy for M Meniere: a comparison of two regimes
    Medical condition: Patients suffering of Menieres disease for at least 6 moths without sufficient relief of symptoms through medicinal therapy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027183 Meniere's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005246-42 Sponsor Protocol Number: 0796-19 Start Date*: 2021-12-28
    Sponsor Name:INTAS PHARMACEUTICALS LIMITED
    Full Title: A Multicenter, Three- arm, Double- blind, Double dummy, Parallel-group, placebo controlled Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once dai...
    Medical condition: Menière´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    20.0 10013993 - Ear and labyrinth disorders 10022398 Inner ear signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000752-32 Sponsor Protocol Number: 04T-617 Start Date*: 2006-01-23
    Sponsor Name:Klinikum Grosshadern
    Full Title: Medical treatment of Menière’s disease with betahistine: a placebo-controlled, dose-finding study
    Medical condition: Ménière’s disease is a disorder of the inner ear membranous labyrinth characterized by paroxysmal vertiginous attacks, fluctuating sensorineural hearing loss, aural fullness, and tinnitus .The unde...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027183 Meniere's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001337-86 Sponsor Protocol Number: 104-201403 Start Date*: 2014-07-11
    Sponsor Name:Otonomy Inc.
    Full Title: A 6-month, prospective, randomized, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease, foll...
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002474-52 Sponsor Protocol Number: AM-125-CL-18-01 Start Date*: 2019-04-01
    Sponsor Name:Auris Medical AG
    Full Title: Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS)
    Medical condition: Treatment of acute peripheral vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10059614 Vestibular vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000766-29 Sponsor Protocol Number: 104-201610 Start Date*: 2016-07-29
    Sponsor Name:Otonomy Inc.
    Full Title: A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE’S DISEASE
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002375-22 Sponsor Protocol Number: 38RC15.173 Start Date*: 2015-07-27
    Sponsor Name:University Hospital Grenoble
    Full Title: Study the diffusion kinetics of gadolinium at the perilymph of the inner ear structures to patients Meniere's disease
    Medical condition: Patients Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005460-80 Sponsor Protocol Number: JMV001 Start Date*: 2006-12-05
    Sponsor Name:N/A
    Full Title: A single center, randomized, open-label, comparative study to assess efficacy and safety of piracetam 4.8g/d administered for 6 months as adjuvant to standard vestibular rehabilitation (VR) therapy...
    Medical condition: moderate to severe vertigo of peripheral origin
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001520-37 Sponsor Protocol Number: KETECT Start Date*: 2014-02-14
    Sponsor Name:Skåne University Hospital, Malmö
    Full Title: Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder
    Medical condition: Major depression disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10019063 Hallucination PT
    18.0 10015919 - Eye disorders 10013036 Diplopia PT
    18.0 100000004863 10061243 Post procedural nausea LLT
    18.0 10029205 - Nervous system disorders 10047343 Vertigo CNS origin PT
    18.0 10037175 - Psychiatric disorders 10015533 Euphoria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013701-34 Sponsor Protocol Number: VMMET009 Start Date*: 2011-09-01
    Sponsor Name:Hospital of the University of Munich
    Full Title: Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo- controlled trial
    Medical condition: vestibular migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001464-35 Sponsor Protocol Number: 104-201811 Start Date*: 2018-11-06
    Sponsor Name:Otonomy, Inc.
    Full Title: A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere’...
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000388-15 Sponsor Protocol Number: VesPa Start Date*: 2016-08-31
    Sponsor Name:University of the University of Munich
    Full Title: Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial
    Medical condition: The main symptoms of vestibular paroxysmia are brief attacks of rotatory or postural vertigo lasting seconds to a few minutes with or without ear symptoms (tinnitus and hypoacusis). As in trigemina...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001540-22 Sponsor Protocol Number: MD2019 Start Date*: 2020-01-22
    Sponsor Name:Abteilung für Hals- Nasen- Ohrenkrankheiten MUW, AKH Wien
    Full Title: Assessment of vertigo control rate following common treatments in Menière´s disease
    Medical condition: In our study we try to evaluate the the effect of common therapies in Menière´s disease patients on vertigo control calculation, Hydrops MRI, vHIT (video head impuls test) , caloric testing, audiol...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 02 00:00:44 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA